Physiomics reports fall in operating loss, rise in turnover

UK biology company Physiomics said operating loss dropped 6.3 per cent in the last half of 2012 as the group signed on new clients and progressed in research and development of products.

UK biology company Physiomics said operating loss dropped 6.3 per cent in the last half of 2012 as the group signed on new clients and progressed in research and development of products.

Operating loss came to £307,685, compared to £328,674 for the same period a year ago, as turnover increased 52.9% to £52,000.

The firm said it signed on a "top five" global pharmaceutical client during the period and was in discussions with others about licencing technology and entering into long-term contracts.

A £4.0m Standby Equity Distribution Agreement was signed with Yorkville, strengthening the position of the company for future growth and acquisition.

Physiomics advanced in developing two new technologies - DrugCARD database and Cardiac toxicity prediction service - which will be launched this year.

First stage of development of the group's Virtual Tumour Clinical, a computer model which analyses tumour cells, is underway as the company works closely with drug discovery and development groups.

"Significant progress has been made during the half year," the group said.

"The customer base has been increased, relationships with existing customers are progressing, new products are soon to come on line and the company's flagship Virtual Tumour Clinical project has begun in earnest, with large pharma already showing an interest in assisting its development.

"While progress on the sales front has been slower than the directors hoped, they believe that the company is establishing the level of credibility required to convert more prospects and is well positioned to deliver more stable sales in the near-term. Successful launch of Virtual Tumour Clinical has the potential to achieve a step-change in growth of revenues."

Shares rose 8.33% to 0.13 at 09:44 Thursday.

RD

Recommended

Four high-quality US stocks to give shelter from the storm
Share tips

Four high-quality US stocks to give shelter from the storm

Professional investor Timothy Parton of the JPMorgan American Investment Trust picks four solid US stocks to buy now.
24 May 2022
Three undervalued mid-cap stocks with attractive prospects
Share tips

Three undervalued mid-cap stocks with attractive prospects

Professional investor Katen Patel of the JPMorgan Mid Cap Investment Trust picks three fast-growing mid-cap stocks to buy now.
24 May 2022
Britain’s ten most-hated shares – w/e 20 May
Stocks and shares

Britain’s ten most-hated shares – w/e 20 May

Rupert Hargreaves looks at Britain's ten-most hated shares, and what short-sellers are looking right now.
23 May 2022
Britain's most-bought shares w/e 20 May
Stocks and shares

Britain's most-bought shares w/e 20 May

A look at Britain's most-bought shares in the week ending 13 May, providing an insight into how investors are thinking and where opportunities may lie…
23 May 2022

Most Popular

Imperial Brands has an 8.3% yield – but what’s the catch?
Share tips

Imperial Brands has an 8.3% yield – but what’s the catch?

Tobacco company Imperial Brands boasts an impressive dividend yield, and the shares look cheap. But investors should beware, says Rupert Hargreaves. H…
20 May 2022
Everything is collapsing at once – here’s what to do about it
Investment strategy

Everything is collapsing at once – here’s what to do about it

Equity and bond markets are crashing, while inflation destroys the value of cash. Merryn Somerset Webb looks at where investors can turn to protect th…
23 May 2022
Barry Norris: we’re already in the 1970s. Here’s how to invest
Investment strategy

Barry Norris: we’re already in the 1970s. Here’s how to invest

Merryn talks to Barry Norris of Argonaut capital about the parallels between now and the 1970s; the transition to “green” energy; and the one sector w…
19 May 2022